Neurological Sciences

, Volume 32, Issue 1, pp 83–88 | Cite as

The effect of natalizumab on cognitive function in patients with relapsing-remitting multiple sclerosis: preliminary results of a 1-year follow-up study

Original Article


The objective of the study was to assess the natalizumab effect on the course of cognitive impairment in patients with relapsing-remitting multiple sclerosis (MS). Patients with active relapsing-remitting MS (n = 17) were treated with natalizumab for 1 year. The quasi control group included patients (n = 7) with clinically stable MS. Assessment of disease course [expanded disability status scale (EDSS); number of relapses] and neuropsychological impairment [Wisconsin card sorting test (WCST); controlled oral word associations; verbal/non-verbal memory tests; paced auditory serial addition test] was conducted at baseline and after 1 year. Natalizumab-treated patients experienced significantly fewer relapses compared with the previous year (P < 0.05). At 1-year follow-up, EDSS score was unchanged and neuropsychological assessments of memory/executive functions showed a significant improvement in natalizumab-treated patients (all P < 0.05). No changes were observed in the quasi control group. This preliminary study suggests that natalizumab could be effective in ameliorating cognitive functions in patients with active relapsing-remitting MS, over 1-year follow-up.


Multiple sclerosis Natalizumab Cognitive function Relapsing-remitting 



The authors thank Wolters Kluwer (Auckland, New Zealand), who provided medical writing support funded by Biogen Idec.


  1. 1.
    IFNB Multiple Sclerosis Study Group (1993) Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. The IFNB Multiple Sclerosis Study Group. Neurology 43:655–661Google Scholar
  2. 2.
    Johnson KP, Brooks BR, Cohen JA, Ford CC, Goldstein J, Lisak RP et al (1995) Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group. Neurology 45:1268–1276PubMedGoogle Scholar
  3. 3.
    Yednock TA, Cannon C, Fritz LC, Sanchez-Madrid F, Steinman L, Karin N (1992) Prevention of experimental autoimmune encephalomyelitis by antibodies against alpha 4 beta 1 integrin. Nature 356:63–66CrossRefPubMedGoogle Scholar
  4. 4.
    Rudick RA, Sandrock A (2004) Natalizumab: alpha 4-integrin antagonist selective adhesion molecule inhibitors for MS. Expert Rev Neurother 4:571–580CrossRefPubMedGoogle Scholar
  5. 5.
    Polman CH, O’Connor PW, Havrdova E, Hutchinson M, Kappos L, Miller DH et al (2006) A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 354:899–910CrossRefPubMedGoogle Scholar
  6. 6.
    Havrdova E, Galetta S, Hutchinson M, Stefoski D, Bates D, Polman CH et al (2009) Effect of natalizumab on clinical and radiological disease activity in multiple sclerosis: a retrospective analysis of the Natalizumab Safety and Efficacy in Relapsing-Remitting Multiple Sclerosis (AFFIRM) study. Lancet Neurol 8:254–260CrossRefPubMedGoogle Scholar
  7. 7.
    Rudick RA, Miller D, Hass S, Hutchinson M, Calabresi PA, Confavreux C et al (2007) Health-related quality of life in multiple sclerosis: effects of natalizumab. Ann Neurol 62:335–346CrossRefPubMedGoogle Scholar
  8. 8.
    Rudick RA, Stuart WH, Calabresi PA, Confavreux C, Galetta SL, Radue EW et al (2006) Natalizumab plus interferon beta-1a for relapsing multiple sclerosis. N Engl J Med 354:911–923CrossRefPubMedGoogle Scholar
  9. 9.
    Deloire MS, Salort E, Bonnet M, Arimone Y, Boudineau M, Amieva H et al (2005) Cognitive impairment as marker of diffuse brain abnormalities in early relapsing remitting multiple sclerosis. J Neurol Neurosurg Psychiatry 76:519–526CrossRefPubMedGoogle Scholar
  10. 10.
    Patti F, Amato MP, Trojano M, Bastianello S, Tola MR, Goretti B et al (2009) Cognitive impairment and its relation with disease measures in mildly disabled patients with relapsing-remitting multiple sclerosis: baseline results from the Cognitive Impairment in Multiple Sclerosis (COGIMUS) study. Mult Scler 15:779–788CrossRefPubMedGoogle Scholar
  11. 11.
    Miller DH, Soon D, Fernando KT, MacManus DG, Barker GJ, Yousry TA et al (2007) MRI outcomes in a placebo-controlled trial of natalizumab in relapsing MS. Neurology 68:1390–1401CrossRefPubMedGoogle Scholar
  12. 12.
    Chiaravalloti ND, DeLuca J (2008) Cognitive impairment in multiple sclerosis. Lancet Neurol 7:1139–1151CrossRefPubMedGoogle Scholar
  13. 13.
    Patti F (2009) Cognitive impairment in multiple sclerosis. Mult Scler 15:2–8CrossRefPubMedGoogle Scholar
  14. 14.
    Poser CM, Paty DW, Scheinberg L, McDonald WI, Davis FA, Ebers GC et al (1983) New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol 13:227–231CrossRefPubMedGoogle Scholar
  15. 15.
    Kurtzke JF (1983) Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 33:1444–1452PubMedGoogle Scholar
  16. 16.
    Gronwall DM (1977) Paced auditory serial-addition task: a measure of recovery from concussion. Percept Mot Skills 44:367–373PubMedGoogle Scholar
  17. 17.
    Berg EA (1948) A simple objective technique for measuring flexibility in thinking. J Gen Psychol 39:15–22CrossRefPubMedGoogle Scholar
  18. 18.
    Novelli G, Papagno C, Capitani E, Laiacona N, Vallar G, Cappa SF (1986) Tre test clinici di ricerca e produzione lessicale.Taratura su soggetti normali. Arch Psicol Neurol Psichiatr 47:477–506Google Scholar
  19. 19.
    Spinnler H, Tognoni G (1987) Standardizzazione e taratura italiana di test neuropsicologici. Ital J Neurol Sci 8(Suppl):1–120Google Scholar
  20. 20.
    Rao SM, Cognitive Function Study Group N (1990) A manual for the brief repeatable battery of neuropsychological tests in multiple sclerosis. National Multiple Sclerosis Society, New YorkGoogle Scholar
  21. 21.
    Meyers J, Meyers K (1995) Rey complex figure and recognition trial: professional manual. Psychological Assessment Resources, OdessaGoogle Scholar
  22. 22.
    Christodoulou C, MacAllister WS, McLinskey NA, Krupp LB (2008) Treatment of cognitive impairment in multiple sclerosis: is the use of acetylcholinesterase inhibitors a viable option? CNS Drugs 22:87–97CrossRefPubMedGoogle Scholar
  23. 23.
    Fischer JS, Priore RL, Jacobs LD, Cookfair DL, Rudick RA, Herndon RM et al (2000) Neuropsychological effects of interferon beta-1a in relapsing multiple sclerosis. Multiple Sclerosis Collaborative Research Group. Ann Neurol 48:885–892CrossRefPubMedGoogle Scholar
  24. 24.
    Patti F, Amato MP, Tola MR, Trojano M, Ferrazza P, Bastianello S (2008) Effects of subcutaneous interferon beta on disease parameters and cognition in patients with early relapsing-remitting multiple sclerosis: longitudinal clinical and cognitive result from the COGIMUS (Cognitive Impairment in Multiple Sclerosis) study. Neurology 70:A87Google Scholar
  25. 25.
    Pliskin NH, Hamer DP, Goldstein DS, Towle VL, Reder AT, Noronha A et al (1996) Improved delayed visual reproduction test performance in multiple sclerosis patients receiving interferon beta-1b. Neurology 47:1463–1468PubMedGoogle Scholar
  26. 26.
    Barak Y, Achiron A (2002) Effect of interferon-beta-1b on cognitive functions in multiple sclerosis. Eur Neurol 47:11–14CrossRefPubMedGoogle Scholar
  27. 27.
    Flechter S, Vardi J, Finkelstein Y, Pollak L (2007) Cognitive dysfunction evaluation in multiple sclerosis patients treated with interferon beta-1b: an open-label prospective 1 year study. Isr Med Assoc J 9:457–459PubMedGoogle Scholar
  28. 28.
    Weinstein A, Schwid SR, Schiffer RB, McDermott MP, Giang DW, Goodman AD (1999) Neuropsychologic status in multiple sclerosis after treatment with glatiramer. Arch Neurol 56:319–324CrossRefPubMedGoogle Scholar
  29. 29.
    Schwid SR, Goodman AD, Weinstein A, McDermott MP, Johnson KP (2007) Cognitive function in relapsing multiple sclerosis: minimal changes in a 10-year clinical trial. J Neurol Sci 255:57–63CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag 2010

Authors and Affiliations

  1. 1.Clinical Neuropsychology UnitSpedali Civili of BresciaBresciaItaly
  2. 2.Multiple Sclerosis CentreSpedali Civili of BresciaBresciaItaly

Personalised recommendations